⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Carbyne Equity Partners and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Carbyne Equity Partners
↗Hamburg, Germany
Carbyne Equity Partners is a private equity firm headquartered in Hamburg, Germany, founded in 2023. The firm focuses on investing in growing European businesses with strong market positions, specifically within the healthcare, nutrition, and agricultural technology sectors.
Carbyne partners with entrepreneurial families and management teams to support R&D-driven businesses. Their investment strategy emphasizes long-term growth, operational support, and leveraging an extensive network of industry experts to accelerate market leadership.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:-
Industry:Pharmaceuticals|Biotechnology|Medical Devices
Sub-Industry:Private Equity / Investment Management
SIZE & FINANCIALS
Employees:1-50
Founded:2023
Ownership:private
Status:operating
0
CORPORATE STRUCTURE
Key Partnerships:ITM (Radiopharmaceuticals), Biomapas (CRO), SuanNutra (Nutraceuticals), Elicit Plant (Agri-tech)
COMPETITION
Position:Niche Player
LEADERSHIP
Key Executives:
Dr. Markus Petersen - Managing Partner
Alexander Winterling - Managing Partner
LINKS
Website:carbynepartners.de
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Carbyne Equity Partners. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.